DNA Damage, Radiation Therapy, Synthetic Lethality , Pancreatic Cancer, Homologous Recombination, RAD18
Type of Research:
Research Interest Statement:
As a physician-scientist, I treat patients with gastrointestinal cancers at the Winthrop P. Rockefeller Cancer Institute using state-of-the-art radiation therapy. My research focus is on discovering novel therapy strategies for the deadly disease of pancreatic cancer. In the lab, I utilize genetic and proteomic approaches to address the fundamental mechanisms of genetic alterations in cancer cells which result in heightened DNA repair leading to radiation and chemotherapy resistance. I recently received a KL2 Mentored Career Development Award in 2021 to investigate the mechanism underlying the role of oncogenic KRAS in regulating the nuclear DNA repair enzyme RAD18, a major promoter of DNA repair in pancreatic cancer.
Sebastian NT, Webb A, Merrell KW, [et al., including Wolfe AR]. Development of a MicroRNA Signature Predictive of Recurrence and Survival in Pancreatic Ductal Adenocarcinoma. Cancers. 2021 13(20). PMID: 34680317. PMCID: PMC8534163.
Wolfe AR, Chablani P, Siedow MR, [et al.]. BRAF mutation correlates with worse local-regional control following radiation therapy in patients with stage III melanoma. Radiation oncology (London, England). 2021 16(1):181. PMID: 34537078. PMCID: PMC8449455.
Memmott RM, Wolfe AR, Carbone DP, Williams TM. Predictors of Response, Progression-Free Survival, and Overall Survival in Patients With Lung Cancer Treated With Immune Checkpoint Inhibitors. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 2021 16(7):1086-1098. PMID: 33845212.
Wolfe AR, Siedow M, Nalin A, [et al.]. Increasing neutrophil-to-lymphocyte ratio following radiation is a poor prognostic factor and directly correlates with splenic radiation dose in pancreatic cancer. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2021 158:207-214. PMID: 33667588.
Vazzano J, Frankel WL, Wolfe AR, [et al.]. Morphologic changes associated with neoadjuvant-treated pancreatic ductal adenocarcinoma and comparison of two tumor regression grading systems. Human pathology. 2021 109:1-11. PMID: 33245985.
Wolfe AR, Robb R, Hegazi A, [et al.]. Altered Gemcitabine and Nab-paclitaxel Scheduling Improves Therapeutic Efficacy Compared with Standard Concurrent Treatment in Preclinical Models of Pancreatic Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2021 27(2):554-565. PMID: 33087331. PMCID: PMC7855515.
Beckham TH, Barney C, Healy E, [et al., including Wolfe AR]. Platinum-based regimens versus cetuximab in definitive chemoradiation for human papillomavirus-unrelated head and neck cancer. International journal of cancer. 2020 147(1):107-115. PMID: 31609479.
Wolfe AR, Prabhakar D, Yildiz VO, [et al.]. Neoadjuvant-modified FOLFIRINOX vs nab-paclitaxel plus gemcitabine for borderline resectable or locally advanced pancreatic cancer patients who achieved surgical resection. Cancer medicine. 2020 9(13):4711-4723. PMID: 32415696. PMCID: PMC7333854.
Wolfe AR, Blakaj D, London N, [et al.]. Clinical Outcomes and Multidisciplinary Patterns of Failure for Olfactory Neuroblastoma: The Ohio State Experience. Journal of neurological surgery. Part B, Skull base. 2020 81(3):287-294. PMID: 32500004. PMCID: PMC7253300.
Wolfe AR, Wald P, Webb A, [et al.]. A microRNA-based signature predicts local-regional failure and overall survival after pancreatic cancer resection. Oncotarget. 2020 11(10):913-923. PMID: 32206188. PMCID: PMC7075466.
Robb R, Yang L, Shen C, [et al., including Wolfe AR]. Inhibiting BRAF Oncogene-Mediated Radioresistance Effectively Radiosensitizes BRAFV600E-Mutant Thyroid Cancer Cells by Constraining DNA Double-Strand Break Repair. Clinical cancer research : an official journal of the American Association for Cancer Research. 2019 25(15):4749-4760. PMID: 31097454. PMCID: PMC6677585.
Wolfe AR, Grecula JC, Blakaj D, [et al.]. Robotic-assisted Intraoperative High-dose Rate Remote Brachytherapy Following Laparoscopic Robotic-assisted Resection of Pelvic Recurrence of Urethral Carcinoma. Advances in radiation oncology. 2019 4(3):443-446. PMID: 31360797. PMCID: PMC6639745.
Wolfe AR, Jain R, Pawlik TM, [et al.]. Radiation-Induced Colitis in a Pancreatic Cancer Patient With a Germline BRCA2 Mutation: A Case Report. Advances in radiation oncology. 2019 4(1):10-14. PMID: 30706003. PMCID: PMC6349605.
Wolfe AR, Williams TM. Altering the response to radiation: radiosensitizers and targeted therapies in pancreatic ductal adenocarcinoma: preclinical and emerging clinical evidence. Annals of pancreatic cancer. 2018 1(8). PMID: 32656528. PMCID: PMC7351115.
Rahal OM, Wolfe AR, Mandal PK, [et al.]. Blocking Interleukin (IL)4- and IL13-Mediated Phosphorylation of STAT6 (Tyr641) Decreases M2 Polarization of Macrophages and Protects Against Macrophage-Mediated Radioresistance of Inflammatory Breast Cancer. International journal of radiation oncology, biology, physics. 2018 100(4):1034-1043. PMID: 29485045.
Stecklein SR, Reddy JP, Wolfe AR, [et al.]. Lack of Breastfeeding History in Parous Women with Inflammatory Breast Cancer Predicts Poor Disease-Free Survival. Journal of Cancer. 2017 8(10):1726-1732. PMID: 28819368. PMCID: PMC5556634.
Wolfe AR, Trenton NJ, Debeb BG, [et al.]. Mesenchymal stem cells and macrophages interact through IL-6 to promote inflammatory breast cancer in pre-clinical models. Oncotarget. 2016 7(50):82482-82492. PMID: 27756885. PMCID: PMC5347707.
Debeb BG, Lacerda L, Anfossi S, [et al., including Wolfe AR]. miR-141-Mediated Regulation of Brain Metastasis From Breast Cancer. Journal of the National Cancer Institute. 2016 108(8). PMID: 27075851. PMCID: PMC5017951.
Wolfe AR, Bambhroliya A, Reddy JP, [et al.]. MiR-33a Decreases High-Density Lipoprotein-Induced Radiation Sensitivity in Breast Cancer. International journal of radiation oncology, biology, physics. 2016 95(2):791-9. PMID: 27055396. PMCID: PMC4851902.
Debeb BG, Lacerda L, Larson R, [et al., including Wolfe AR]. Histone deacetylase inhibitor-induced cancer stem cells exhibit high pentose phosphate pathway metabolism. Oncotarget. 2016 7(19):28329-39. PMID: 27078845. PMCID: PMC5053589.
Wolfe AR, Debeb BG, Lacerda L, [et al.]. Simvastatin prevents triple-negative breast cancer metastasis in pre-clinical models through regulation of FOXO3a. Breast cancer research and treatment. 2015 154(3):495-508. PMID: 26590814. PMCID: PMC5901982.
Wolfe AR, Woodward WA. Breast Cancer Stem Cell Correlates as Predicative Factors for Radiation Therapy. Seminars in radiation oncology. 2015 25(4):251-9. PMID: 26384273.
Wolfe AR, Atkinson RL, Reddy JP, [et al.]. High-density and very-low-density lipoprotein have opposing roles in regulating tumor-initiating cells and sensitivity to radiation in inflammatory breast cancer. International journal of radiation oncology, biology, physics. 2015 91(5):1072-80. PMID: 25832697. PMCID: PMC4801170.